News

Two distinct proteins previously known to play key roles in the development of tremor associated with neurodegenerative diseases now have been found to interact directly, a discovery that might lead to new therapies for tremor-related movement disorders, including Parkinson’s disease. The study with that finding, “LINGO1 is a…

A non-contact boxing program could improve quality of life and willingness to exercise in people with Parkinson’s disease, new data shows. A preliminary study with these findings will be presented at the American Academy of Neurology‘s Annual Meeting, to be held in Toronto at the end of…

Enrollment in the Phase 1/2 PROPEL trial, evaluating the safety, tolerability, and early efficacy of PR001 — a one-time gene therapy — for Parkinson’s disease associated with mutations in the GBA1 gene, is progressing at two centers in New York and patient dosing is continuing. Prevail Therapeutics,…

The first patient has been dosed in a Phase 2 study testing NLY01, an investigational compound with a new mechanism of action designed to stall the progression of Parkinson’s disease. NLY01, being developed by Neuraly, could prevent nerve cell loss in the brain by stopping the…

To make it easier for Parkinson’s (PD) patients and healthy volunteers to take part in clinical trials, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is introducing a redesigned version of its Fox Trial Finder clinical study matching tool. “At the Foundation, our single urgent goal…

Tai chi improves motor function in people with mild to moderate Parkinson’s disease and may slow down disease progression, a new study has found. The study, “Tai Chi versus routine exercise in patients with early- or mild-stage Parkinson’s disease: a retrospective cohort analysis,” was published…

An investigational therapy known as NLX-112 (befiradol) may hold promise to treat levodopa-induced dyskinesia, a complication of long-term levodopa therapy that affects people with Parkinson’s disease, a study found. The study, “The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets,” was…

In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The response…

Blood levels of progranulin — a protein whose deficiency has been linked to neurodegeneration — may reflect Parkinson’s severity and progression, and serve as a disease biomarker, a recent study suggested. The research, “Reduced plasma progranulin levels are associated with the severity of Parkinson’s disease,” was published in…

A new technique using tiny bubbles and ultrasound waves could ease the way for gene therapy to be delivered to the central nervous system, a mouse study suggests. The technique had a neuroprotective effect on mice, and those treated to model Parkinson’s showed improvements in measurements of motor function,…